Tagreed Alkaltham: Blood Management in Times of Crisis
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Blood Management in Times of Crisis
Governance, Structure, and Strategic Readiness
- In transfusion medicine, crises do not test emotion.
- They test systems.
Effective blood management during high demand events is not built at the moment of activation.
It is designed through governance, structured inventory models, and clearly defined escalation pathways long before urgency emerges.
From a leadership perspective, crisis readiness in transfusion services rests on four foundational dimensions:
1 . Strategic Inventory Planning:
Maintaining adequate supply requires more than volume.
It requires defined minimum thresholds, emergency buffer allocation, and continuous monitoring of high risk blood groups and phenotypes.
Resilience is not excess.
It is controlled preparedness.
2. Structured Escalation Frameworks:
Crisis activation must follow predefined criteria, not subjective urgency.
Clear command structures, decision authority, and communication channels determine operational stability under pressure.
Systems function best when authority is clarified before it is needed.
3. Ethical Allocation Governance:
In periods of increased demand, allocation decisions must remain clinically justified, transparent, and policy driven.
Equity in distribution protects both patients and institutional integrity.
4. Operational and Workforce Preparedness:
Simulation drills, cross training, fatigue mitigation, and surge planning ensure continuity of service without compromising safety.
Operational strength is a product of preparation, not reaction.
- Preparedness is not a temporary state.
- It is a leadership discipline sustained over time
- Strong systems do not rely on urgency to function.
- They rely on structure.
Governance designed in stability
is what protects performance under pressure.”
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH